Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3 Internal Tandem Duplication (ITD)

NCT03622541 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT03622541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03622541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3 Internal Tandem Duplication (ITD)
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
November 15, 2010
Completion date
March 1, 2020
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aml, flt3-itd mutation